PROGNOSTIC IMPACT OF THE MAXIMAL EVALUABLE LESION SIZE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB PLUS IPILIMUMAB COMBINATION THERAPY

被引：0
|
作者：
Mita, Yoshie
Teishima, Jun
Hara, Takuto
Bando, Yukari
Suzuki, Kotaro
Terakawa, Tomoaki
Chiba, Koji
Miyake, Hideaki
机构：
来源：
JOURNAL OF UROLOGY | 2025年 / 213卷 / 5S期
关键词：
D O I：
10.1097/01.JU.0001110068.14710.ff.17
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP28-17
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Real-world outcomes in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab
    Doshi, Gurjyot K.
    Robert, Nicholas J.
    Chen, Liwei
    Chan, Philip K.
    Del Tejo, Viviana
    Stwalley, Brian
    Huo, Stephen
    Geynisman, Daniel M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [32] Efficacy and safety of first-line combination therapy with ipilimumab plus nivolumab for metastatic renal cell carcinoma in a single institution in Japan
    Nagata, M.
    Horie, S.
    Nagaya, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S1566 - S1567
  • [33] Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non- Clear Cell Renal Cell Carcinoma
    Gupta, Ruby
    Ornstein, Moshe Chaim
    Li, Hong
    Allman, Kimberly D.
    Wood, Laura S.
    Gilligan, Timothy
    Garcia, Jorge A.
    Von Merveldt, Dendra
    Hammers, Hans J.
    Rini, Brian I.
    CLINICAL GENITOURINARY CANCER, 2020, 18 (06) : 429 - 435
  • [34] Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma
    Gao, Xin
    McDermott, David F.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (09) : 947 - 957
  • [35] Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab
    Nakayama, Takayuki
    Takeshita, Hideki
    Kagawa, Makoto
    Washino, Satoshi
    Shirotake, Suguru
    Miura, Yuji
    Hyodo, Yoji
    Izumi, Keita
    Inoue, Masaharu
    Matsuoka, Yoh
    Miyagawa, Tomoaki
    Oyama, Masafumi
    Saito, Kazutaka
    Kawakami, Satoru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (10) : 1528 - 1537
  • [36] Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma
    Segawa, Takuya
    Motoshima, Takanobu
    Yatsuda, Junji
    Kurahashi, Ryoma
    Fukushima, Yumi
    Murakami, Yoji
    Yamaguchi, Takahiro
    Sugiyama, Yutaka
    Yoshida, Ryoji
    Nakayama, Hideki
    Kamba, Tomomi
    IJU CASE REPORTS, 2023, 6 (02) : 147 - 149
  • [37] A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma
    Kato, Renpei
    Kojima, Takahiro
    Sazuka, Tomokazu
    Yamamoto, Hayato
    Fukuda, Shohei
    Yamana, Kazutoshi
    Sugino, Yusuke
    Hamamoto, Shuzo
    Nakaigawa, Noboru
    Kabu, Koki
    Murakami, Hiroshi
    Obara, Wataru
    ANTICANCER RESEARCH, 2021, 41 (12) : 6199 - 6209
  • [38] Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC).
    Gul, Anita
    Shah, Neil J.
    Mantia, Charlene
    Hammers, Hans J.
    Ornstein, Moshe Chaim
    McDermott, David F.
    Atkins, Michael B.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [39] PHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M.
    Rini, B. I.
    McDermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M.
    Sharma, P.
    Kollmannsberger, C. K.
    Heng, D.
    Shen, Y.
    Kurland, J.
    Spratlin, J.
    Gagnier, P.
    Amin, A.
    ANNALS OF ONCOLOGY, 2014, 25
  • [40] The predictive biomarker for immune-related adverse events (irAEs) in patients with metastatic renal cell carcinoma treated with the combination therapy of nivolumab plus ipilimumab: Musashino study-irAE
    Kizawa, R.
    Kuno, M.
    Washino, S.
    Shirotake, S.
    Izumi, K.
    Inoue, M.
    Kagawa, M.
    Takeshita, H.
    Hyodo, Y.
    Kawakami, S.
    Saito, K.
    Kageyama, Y.
    Oyama, M.
    Miyagawa, T.
    Miura, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1488 - S1488
12345